Gene therapy: Applications to the neurosciences and to neurological disease

Neuroscientist

Volumn 4, Issue 6, 1998, Pages 398-407

  Tuszynski, Mark H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Adeno associated virus; Alzheimer disease; Cancer; Gene therapy; Parkinson disease; Retrovirus; Spinal cord injury

Indexed keywords

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; CANCER; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; MEDICAL RESEARCH; NONHUMAN; PARKINSON DISEASE; RETROVIRUS; REVIEW; SPINAL CORD INJURY; TRANSGENE;

EID: 0031795165     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849800400612     Document Type: Review

References (60)

1. Reed JC, Zha H, Aime-Sempe C, Takayama S, Wang HG. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol 1996;406:99-112.
2. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-76.
3. Waxman SG. Molecular remodeling of neurons in multiple sclerosis: what we know, and what we must ask about brain plasticity in demyelinating diseases. Adv Neurol 1997;73:109-120.
4. Schmidt S, Linington C, Zipp F, et al. Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 1997;120:1437-1445.
5. Hermans G, Stinissen P, Hauben L, Van den Berg-Loonen E, Raus J, Zhang J. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 1997;42: 18-27.
6. Vandenbroeck K, Martino G, Marrosu M, et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 1997;76:189-192.
7. Pollard H, Bugra K, Khrestchatisky M, Represa A, Ben-Ari Y. Seizure-induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers. Epilepsy Res Suppl 1996;12:355-363.
8. Clough RW, Eells JB, Browning RA, Jobe PC. Seizures and protooncogene expression of fos in the brain of adult genetically epilepsy-prone rats. Exp Neurol 1997;146:341-353.
9. Seeger M, Nordstedt C, Petanceska S, et al. Evidence for phosphorylation and oligomeric assembly of presenilin 1. Proc Natl Acad Sci U S A 1997;94:5090-5094.
10. Selkoe DJ. Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harbor Symp Quant Biol 1996;61:587-596.
11. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77.
12. Delihas N, Rokita SE, Zheng P. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design. Nat Biotechnol 1997;15:751-753.
13. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-480.
14. Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997;8: 15-25.
15. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-831.
16. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
17. Eck SL, Alavi JB, Alavi A, et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996;7:1465-1482.
18. Stephan D, Nabel EG. Gene and other biological therapies for vascular diseases. Fundam Clin Pharmacol 1997;11:97-110.
19. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997;107(Suppl 1):41-44.
20. Evans CH, Robbins PD, Ghivizzani SC, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996;7:1261-1280.
21. Mendell JR, Kissel JT, Amato AA, et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995; 333:832-838.
22. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997;389:239-242.
23. Watson JD, Tooze J, Kurtz DT. Recombinant DNA. A short course. New York: W.H. Freeman and Company/Scientific American Books; 1983.
24. Blau HM, Springer ML. Gene therapy - a novel form of drug delivery. N Engl J Med 1995;333:1204-1207.
25. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997;94:1426-1431.
26. Tuszynski MH, Gabriel K, Gage FH, Suhr S, Meyer S, Rosetti A. Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory, motor and noradrenergic neurites after adult spinal cord injury. Exp Neurol 1996;137:157-173.
27. Chen KS, Gage FH. Somatic gene transfer of NGF to the aged brain: Behavioral and morphological amelioration. J Neurosci 1995; 15:2819-2825.
28. Crain SM. Physiology of CNS tissue in culture. In: Berl S, Clarke DD, Schneider DD, eds. Metabolic compartmentation and neurotransmission. Relation to brain structure and function. New York: Plenum; 1975. p. 273-303.
29. Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J Neurosci 1997;17:5560-5572.
30. Brustle O, McKay RD. Neuronal progenitors as tools for cell replacement in the nervous system. Curr Opin Neurobiol 1996;6:688-695.
31. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992;12:4565-4574.
32. Terry RD, Katzman R, Bick KL. Alzheimer Disease. New York: Raven Press; 1994.
33. Hefti F. Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci 1986;6: 2155-2162.
34. Tuszynski MH, U SH, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991;30:625-636.
35. Winkler J, Ramirez GA, Kuhn HG, et al. Reversible induction of Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in vivo after continuous intracerebroventricular administration of nerve growth factor. Ann Neurol 1996;40:128-139.
36. Rosenberg MB, Friedmann T, Robertson RC, et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 1988;242:1575-1578.
37. Fischer W, Bjorklund A, Chen K, Gage FH. NGF improves spatial memory in aged rodents as a function of age. J Neurosci 1991;11: 1889-1906.
38. Martinez-Serrano A, Fischer W, Bjorklund A. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain. Neuron 1995;15:473-484.
39. Tuszynski MH, Roberts J, Senut MC, U H-S, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy 1996;3:305-314.
40. Emerich DW, Winn S, Harper J, Hammang JP, Baetge EE, Kordower JH. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 1994;349:148-164.
41. Tuszynski MH, Smith D, Gage FH, Roberts J. Effects of NGF-secreting cells on cholinergic neurons in aged primates. Soc Neurosci Abstr 1996;22:751.
42. Friden PM, Walus LR, Watson P, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993;259: 373-377.
43. Winkler J, Suhr ST, Gage FH, Thai LJ, Fischer L. Essential role of neocortical acetylcholine in spatial memory. Nature 1995;375:484-487.
44. Freese A, Stern M, Kaplitt MG, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996;11:469-488.
45. Wolff JA, Fisher LJ, Xu L, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1989;86:9011-9014.
46. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci 1993;13:5203-5211.
47. Leff SE, Wu F, Unruh C, et al. Coexpression of human GTP cyclohydrolase I (GTPCH1) and human tyrosine hydroxylase cDNAs to potentiate L-DOPA production by fibroblasts: Applications to Parkinson's disease gene therapy. Soc Neurosci Abstr 1995;21: 1272.
48. Emerich DF, Hammang JP, Baetge EE, Winn SR. Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Exp Neurol 1994; 130:141-150.
49. Kordower JH, Chen EY, Mufson EJ, Winn SR, Emerich DF. Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons. Neuroscience 1996;72: 63-77.
50. Tuszynski MH, Gage FH. Bridging grafts and transient NGF infusions promote long-term CNS neuronal rescue and partial functional recovery. Proc Natl Acad Sci USA 1995;92:4621-4625.
51. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME. Recovery from spinal cord injury by antibodies to neurite growth inhibitors. Nature 1995;378:498-501.
52. Tuszynski MH, Murai K, Blesch A, Grill R, Miller I. Functional characterization of NGF-secreting cell grafts to the acutely injured spinal cord. Cell Transplant 1997;6:361-368.
53. Tuszynski MH, Peterson DA, Ray J, Baird A, Nakahara Y, Gage FH. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 1994;126:1-14.
54. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.
55. Xu XM, Guenard V, Kleitman N, Bunge MB. Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord. J Comp Neurol 1995;351:145-160.
56. Tuszynski MH, Weidner N, McCormack M, Miller I, Powell H, Conner J. Grafts of genetically modified Schwann cells to the spinal cord: Survival, axon growth and myelination. Cell Transplant 1998; 7:187-196.
57. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993;79:729-735.
58. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996;56:2697-2702.
59. Gossen M, Bonin AL, Freundlieb S, Bujard H. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol 1994;5:516-520.
60. Suhr S, Gage FH. Gene therapy for neurological disease. Arch Neurol 1993;50:1252-1268.